BioNTech SE American Depositary Share (BNTX) Financials
Key financial figures for BioNTech SE American Depositary Share (Q2 2026), as reported in EUR.
BioNTech SE reported revenue of 105.6 million EUR for Q2 FY2026, down 59.5% from the same period a year earlier. The company posted a net loss of 820.8 million EUR, or -3.24 EUR per share. Operating margin came to -897.82%, against -192.14% a year earlier. Free cash flow for the period was -44.8 million EUR. Across the last 5 reported quarters, quarterly revenue has moved from 260.8 million EUR in Q2 FY2025 to 105.6 million EUR in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for BioNTech SE are on the SentiSense financials page.
- Revenue
- EUR 106M
- Net Income
- -EUR 821M
- EPS
- EUR -3.24
- Total Assets
- EUR 20.3B
- Operating Cash Flow
- EUR 11M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | EUR 106M | -EUR 821M | -EUR 3.24 | -897.82% | -EUR 45M |
| Q1 FY2026 | EUR 120M | -EUR 541M | -EUR 2.14 | -559.78% | -EUR 486M |
| Q4 FY2025 | EUR 899M | -EUR 302M | -EUR 1.23 | -25.66% | EUR 238M |
| Q3 FY2025 | EUR 1.5B | -EUR 29M | -EUR 0.12 | -3.09% | EUR 811M |
| Q2 FY2025 | EUR 261M | -EUR 387M | -EUR 1.60 | -192.14% |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | EUR 2.8B | -EUR 1.1B | -EUR 4.51 | -22.63% | EUR 270M |
| FY2024 | EUR 2.8B | -EUR 665M | -EUR 2.77 | -47.77% | -EUR 245M |
| FY2023 | EUR 3.8B | EUR 930M | EUR 3.83 | 18.08% | EUR 4.7B |
Frequently asked questions
What was BioNTech SE's revenue last quarter?
BioNTech SE reported revenue of 105.6 million EUR for Q2 FY2026, down 59.5% from the same period a year earlier.
Is BioNTech SE profitable?
Not in its most recent reported period. BioNTech SE reported a net loss of 820.8 million EUR for Q2 FY2026, a net margin of -777.27% on revenue.
How has BioNTech SE's margin trended?
Operating margin was -897.82% in Q2 FY2026, compared with -192.14% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did BioNTech SE generate?
BioNTech SE generated free cash flow of -44.8 million EUR in Q2 FY2026, after capital expenditure.
Figures are as reported by the filer in EUR and are not converted to US dollars. The share price is quoted in US dollars, so the two are not directly comparable.
Full income statement, balance sheet and cash flow for BioNTech SE American Depositary Share on SentiSense, with up to forty quarters and twenty fiscal years of history.